Posts Tagged: California Stem Cell Report
Monica Nava and her 1-year-old daughter Clementine, who suffers from the "bubble baby" affliction. (Family photo).
The story about Jakob, Sheersha and Clementine is a 6,000-mile biomedical tale that spans the Atlantic. The story ranges from the Saskatchewan River in Canada to the dusty Tehachapi mountains in drought-plagued Southern California. And it is a story of children with a terrible and rare genetic affliction known as the bubble baby disease.
A scientist at work in a biomedical laboratory. (Photo: Tom Robertson, via Shutterstock)
The California stem cell agency says it is doing “everything” it can to move forward on a gene therapy that has saved the lives of more than 50 persons but which has been pushed aside by the company that has exclusive rights to it. The issue has raised questions about the ethics of withholding care from babies and children suffering from a fatal disease.
Stem cell researcher and professor Larry Goldstein. (Photo: Screen capture, UCTV).
Larry Goldstein, a well-known stem cell researcher at the University of California, San Diego who has received nearly $22 million in awards from the California stem cell agency, today was named to its governing board. It was the first time in the history of the 16-year-old agency that a scientist who has received agency awards has been appointed to the board.
A scientist with a pipette doing cellular research. (Photo: 18percentgrey, via Shutterstock)
OPINION: At a time of budget crisis, Proposition 14 commits California to spending $5 billion (plus interest) that we don’t have, on a bureaucracy we don’t need, in pursuit of cures no one can guarantee. Specifically, Prop. 14 would refinance the California Institute for Regenerative Medicine (CIRM), also known as the state stem cell agency.
Robert Klein, left, and CIRM board member Jeff Sheey, right. At center is Board Vice Chair Art Torres. (Photo: California Stem Cell Report)
The two men once worked together over the last 16 years to spend $3 billion in state funds on stem cell research in California. This week, however, they were very publicly on opposite sides of a ballot initiative to spend $5.5 billion more. The initiative is Proposition 14, which would require the state to borrow the additional billions.
A medical researcher examines cancer stem cells. (Photo: luchschenF, via Shutterstock)
Over the last 15 years, California’s stem cell agency has spent $2.7 billion on research on everything from cancer to arthritis. The vast majority of the money has gone to enterprises that have ties to members of the agency’s governing board. Eight out of every ten dollars that agency has handed out have been collected by 25 institutions such as Stanford University, multiple campuses of the University of California and scientific research organizations. Their combined total exceeds $2.1 billion.
California Gov. Gavin Newsom just before a meeting in Sacramento. ((Photo: Matt Gush, cvia Shutterstock)
Gov. Gavin Newsom, long a supporter of the California stem cell agency, today endorsed Proposition 14, the November ballot measure to give the agency $5.5 billion more and save it from financial extinction.
A laboratory stem cell researcher uses a laptop in conjunction with a microscope. (Photo: moreimages, via Shutterstock)
A small firm in Menlo Park, Ca., is probably the only company in the nation that is named after the number of a particular human protein. It is a small number too, only 47. But it has large implications for California’s financially strapped state stem cell agency.
A scientist examines cells in a biological laboratory. (Photo: anyalvanova, via Shutterstock)
The man expected to lead the drive for $5.5 billion more for California’s stem cell agency today said the Trump restrictions on fetal tissue research represent a dangerous precedent that threatens the health of all Americans.
Robert Klein addresses a meeting of two governing board committees of the California Institute for Regenerative Medicine. (Photo: David Jensen, California Stem Cell Report)
Facing the likelihood of a slow and withering death, the California stem cell agency is edging gingerly forward on a path of “cuts” and risky fund-raising in hopes that its research results will soon generate voter support for more billions of dollars. Two governing board committees of the $3 billion agency, formally known as the California Institute for Regenerative Medicine (CIRM), on Monday. Nov. 27, recommended that the full board “entertain” the proposals at its Dec. 14 meeting.